Search
AVR-RD-05
go.drugbank.com/drugs/DB18631ExperimentalIt is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII). … AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced _ex vivo_ with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme.
Dihydroxyacetone
go.drugbank.com/drugs/DB01775ExperimentalIt is readily phosphorylated to dihydroxyacetone phosphate by triokinase in erythrocytes. In combination with naphthoquinones it acts as a sunscreening agent. [PubChem] … Its addition to blood preservation solutions results in better maintenance of 2,3-diphosphoglycerate levels during storage.
Romifidine
go.drugbank.com/drugs/DB11543ExperimentalVet approvedRomifidine is a veterinary drug utilized as a sedative primarily in large animals, most frequently horses. It is also used less commonly in a wide variety of other animal species. … This drug's chemical structure closely resembles that of clonidine, however, romifidine is not approved for use in humans.
Cimetropium
go.drugbank.com/drugs/DB09271InvestigationalIt is also endowed of a direct myolitic action which partially accounts for its antispasmodic activity. It has never been approved for use in the U.S. or Canada. … Cimetropium is a semi-synthetic belladonna alkaloid and derivative of scopolamine. It is a potent antimuscarinic and an effective antispasmodic drug.
Morus alba root bark
go.drugbank.com/drugs/DB14271InvestigationalMorus alba root bark is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Magnolia kobus flowering top
go.drugbank.com/drugs/DB14319InvestigationalMagnolia kobus flowering top is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Zanthoxylum clava-herculis bark
go.drugbank.com/drugs/DB14379ExperimentalZanthoxylum clava-herculis bark is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
TT-232
go.drugbank.com/drugs/DB12088InvestigationalTln 232 is under investigation in clinical trial NCT00422786 (Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma).